Mission Statement, Vision, & Core Values (2026) of Jilin Aodong Pharmaceutical Group Co., Ltd.

Rooted in Dunhua and publicly traded since 1996, Jilin Aodong Pharmaceutical Group blends tradition and scale-established in 1993, the state-owned firm now offers over 200 varieties of Chinese patent and chemical drugs, exports to over 30 countries, and reported CNY 2.79 billion in revenue for 2022 with a year-on-year rise of +8.2%, while the workforce reached 5,745 employees as of December 31, 2024; its mission emphasizes GMP-compliant quality, patient-centric affordability and sustainability, backed by R&D investment of approximately CNY 150 million (≈10% of revenue), and its vision targets first-class global competitiveness-seeking a 30% increase in international sales by 2025-driven by core values of quality, innovation, integrity, collaboration and environmental responsibility.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) - Intro

• Founded: 1993; Listed: Shenzhen Stock Exchange, 1996
• Headquarters: Dunhua, Jilin, China
• Workforce: 5,745 employees as of December 31, 2024 (up 1.75% YoY)
• Product portfolio: Over 200 varieties, including TCM patent drugs and chemical pharmaceuticals
• Export reach: Products exported to 30+ countries

• Deliver safe, effective, and accessible medicines rooted in TCM heritage and modern pharmaceutical science.
• Promote public health through quality manufacturing, regulatory compliance, and continuous R&D.

• Be a leading integrated pharmaceutical group that bridges traditional Chinese medicine and contemporary therapeutics at home and abroad.
• Establish recognized global brands built on efficacy, safety, and sustainable growth.

• Patient-centered quality: prioritize safety and clinical efficacy through strict quality control and GMP-compliant production.
• Integrity and compliance: adhere to regulatory standards, ethical commercialization, and transparent corporate governance.
• Innovation and R&D: invest in product improvement, formulation modernization, and new indications for traditional remedies.
• Employee development: foster skills, safety, and career growth for a workforce of 5,745 (2024).
• Global responsibility: expand exports responsibly to more than 30 countries while maintaining environmental and social governance.

• Portfolio optimization: maintain and grow the >200-product lineup with emphasis on high-margin, clinically validated items.
• Market expansion: leverage export channels to deepen presence across Asia, Africa, and selected Western markets.
• Efficiency & margins: use scale and packaging expertise to control COGS while targeting revenue growth beyond 8% YoY when feasible.
• R&D and collaboration: develop integrated R&D projects combining TCM theory and modern pharmacology to create differentiated products.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) - Overview

• Mission focus: Innovation, quality, patient-centric care, affordability, and sustainable operations.
• Quality assurance: Facilities and production processes aligned with Good Manufacturing Practices (GMP) to meet domestic and export standards.
• R&D commitment: Targeted investment to develop new formulations, generics, and specialty products that address local and regional public health needs.
• Patient access: Pricing and distribution strategies intended to improve availability of essential medicines.

• Strategic R&D areas: formulation optimization, therapeutic generics, and quality control technologies.
• Sustainability aims: integrate resource-efficient manufacturing and waste-minimization practices across plants.
• Patient-centered initiatives: programs to improve access and affordability in regional markets.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) - Mission Statement

• To improve global health and well‑being by developing, producing and delivering safe, effective and affordable pharmaceutical and healthcare products that meet patient needs across markets.
• To advance pharmaceutical innovation through sustained R&D investment, rigorous quality systems and strategic partnerships that accelerate access to therapies worldwide.
• To create long‑term value for patients, employees, shareholders and communities while embedding sustainability across the value chain.

• To become a first‑class enterprise in the global pharmaceutical and healthcare markets by achieving global competitiveness in product quality, innovation and patient‑centric service.
• To expand international reach with a targeted 30% increase in international sales by 2025 and to scale export channels, licensing and overseas partnerships accordingly.
• To balance growth with environmental responsibility by integrating sustainable manufacturing, waste reduction and energy efficiency into operations.
• To accelerate capability building through strategic acquisitions and alliances that strengthen R&D pipelines, manufacturing capacity and global distribution.

• Patient First - decisions and product development prioritize safety, efficacy and patient outcomes.
• Innovation - continuous investment in R&D, clinical development and technology adoption to deliver differentiated therapies.
• Quality and Compliance - adherence to international GMP, regulatory standards and robust quality management at every production stage.
• Integrity and Transparency - ethical conduct, transparent reporting and strong corporate governance.
• Sustainability - commitment to reducing environmental impact and promoting social responsibility.

• Drive export channel expansion and regulatory approvals in priority markets to meet the 30% international sales increase target.
• Allocate incremental capital to R&D and clinical programs to strengthen the mid‑term pipeline while protecting margins.
• Invest in manufacturing modernization and digital quality systems to ensure compliance and scalability.
• Seek strategic M&A and licensing opportunities that complement core competencies and speed market access.
• Implement measurable sustainability programs (energy, emissions, waste) with public reporting of progress.

Jilin Aodong Pharmaceutical Group Co., Ltd. (000623.SZ) - Vision Statement

• Commitment to quality: rigorous GMP-compliant manufacturing and international quality certifications to ensure product safety and efficacy.
• Innovation-driven growth: sustained investment in R&D to accelerate new drug development and lifecycle optimization of core products.
• Patient-centric access: pricing and distribution strategies that improve affordability and availability of essential medicines.
• Sustainability focus: emission reduction, waste management, and resource-efficient manufacturing as operational priorities.
• Integrity and compliance: adherence to ethical standards, regulatory compliance, and transparent corporate governance.
• Collaborative partnerships: strategic alliances with domestic and international research institutions and industry partners to co-develop and commercialize therapeutics.

Key performance and strategic metrics (latest fiscal year basis where available):

• Quality metrics: batch release rejection rates kept below industry benchmarks through robust QA/QC systems.
• Innovation metrics: pipeline includes multiple generic upgrades and specialty formulations; active clinical and preclinical programs funded by internal R&D.
• Affordability initiatives: pricing tiers and hospital tender participation to maintain accessibility for essential medicines.
• Sustainability targets: initiatives to reduce water and energy intensity per unit of output, and to increase hazardous-waste treatment compliance.
• Governance & compliance: ongoing internal audits, third-party regulatory inspections, and public financial disclosures to ensure transparency.
• Collaborative footprint: partnerships with academic institutes and contract research organizations to accelerate development timelines and broaden market access.

Stakeholder-oriented KPIs integrated into operational planning:

Operationalizing the vision involves cross-functional execution: expanding R&D pipelines, upgrading production capacity, strengthening hospital and retail channels, and deepening international partnerships. For investors and stakeholders seeking more context: Exploring Jilin Aodong Pharmaceutical Group Co., Ltd. Investor Profile: Who's Buying and Why?